Predictability of Liver-Related Seromarkers for the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Lin, Yu Ju ^a,b   Lee, Mei Hsuan ^a,b   Yang, Hwai I ^b,c,d   Jen, Chin Lan ^b   You, San Lin ^b   Wang, Li Yu ^e   Lu, Sheng Nan ^f   Liu, Jessica ^b   Chen, Chien Jen ^b,g  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e MACKAY MEDICAL COLLEGE   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; HEPATITIS B(E) ANTIGEN;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER RISK; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; HEPATITIS B; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEROLOGY;

ADULT; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84876229046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061448     Document Type: Article

References (30)

1. Chen CJ, Yang HI, (2011) Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 26: 628-638.
2. El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273 e1261.
3. Ott JJ, Stevens GA, Groeger J, Wiersma ST, (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 2212-2219.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
5. Morgan TR, Mandayam S, Jamal MM, (2004) Alcohol and hepatocellular carcinoma. Gastroenterology 127: S87-96.
6. Fattovich G, Stroffolini T, Zagni I, Donato F, (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127: S35-50.
7. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, et al. (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347: 168-174.
8. Chen CJ, Yang HI, Iloeje UH, (2009) Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 49: S72-84.
9. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, et al. (2004) Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53: 1494-1498.
10. Kao JH, Chen PJ, Lai MY, Chen DS, (2003) Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124: 327-334.
11. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, et al. (2009) Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 50: 80-88.
12. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, et al. (2010) Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 28: 1660-1665.
13. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, et al. (2010) Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 28: 2437-2444.
14. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, et al. (2011) Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 12: 568-574.
15. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531.
16. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, et al. (2007) Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 12: 1295-1303.
17. Aghemo A, Lampertico P, Colombo M, (2012) Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. J Hepatol 57: 1326-1335.
18. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069-1075.
19. Baranova A, Lal P, Birerdinc A, Younossi ZM, (2011) Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 11: 91.
20. Iloeje UH, Yang HI, Su J, Jen CL, You SL, et al. (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130: 678-686.
21. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430.
22. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, et al. (2003) Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 163: 218-224.
23. Grimes DA, Schulz KF, (2005) Refining clinical diagnosis with likelihood ratios. Lancet 365: 1500-1505.
24. DeLong ER, DeLong DM, Clarke-Pearson DL, (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845.
25. Sullivan LM, Massaro JM, D'Agostino RB Sr, (2004) Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 23: 1631-1660.
26. Yang JD, Roberts LR, (2010) Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7: 448-458.
27. Sawabu N, Nakagen M, Ozaki K, Wakabayashi T, Toya D, et al. (1983) Clinical evaluation of specific gamma-GTP isoenzyme in patients with hepatocellular carcinoma. Cancer 51: 327-331.
28. Eriksson S, Carlson J, Velez R, (1986) Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 314: 736-739.
29. Peng CY, Chien RN, Liaw YF (2012) Hepatitis B virus-related decompensated liver disease: Benefits of antiviral therapy. J Hepatol.
30. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, et al. (2008) Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int 28: 1408-1416.